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Abstract Epothilones are myxobacterial natural products
that inhibit human cancer cell growth through the stabil-
ization of cellular microtubules (i.e., a “taxol-like” mech-
anism of action). They have proven to be highly productive
lead structures for anticancer drug discovery, with at least
seven epothilone-type agents having entered clinical trials in
humans over the last several years. SAR studies on epothil-
ones have included a large number of fully synthetic ana-
logs and semisynthetic derivatives. Previous reviews on the
chemistry and biology of epothilones have mostly focused on
analogs that were obtained by de novo chemical synthesis. In
contrast, the current review provides a comprehensive over-
view on the chemical transformations that have been investi-
gated for the major epothilones A and B as starting materials,
and it discusses the biological activity of the resulting prod-
ucts. Many semisynthetic epothilone derivatives have been
found to exhibit potent effects on human cancer cell growth
and several of these have been advanced to the stage of clini-
cal development. This includes the epothilone B lactam ixab-
epilone (Ixempra), which has been approved by the FDA
for the treatment of advanced and metastatic breast cancer.
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Introduction
Microtubule-interacting agents (MSA) are an important class
of antitumor agents [1], which are in use for the treatment of
a variety of cancers, either as single agents or as part of com-
bination chemotherapy [2,3]. MSA can be divided into two
distinct functional classes, namely compounds that inhibit
the assembly of soluble tubulin into microtubule polymers
(“tubulin polymerization inhibitors”) and those that promote
the assembly of tubulin heterodimers into microtubule poly-
mers and stabilize microtubules (“microtubule stabilizers”)
[4]. Among microtubule stabilizers the natural product taxol
(paclitaxel; Taxol) and its semisynthetic analog docetaxel
(Taxotere) (Fig. 1) are an important part of today’s arma-
mentarium for the pharmacotherapy of cancer [5].
After the elucidation of taxol’s mode of action in 1979
[6], it took more than a decade before other microtubule-
stabilizing agents with non-taxol-like structures were dis-
covered. Most prominent among these new microtubule
stabilizers are the epothilones, which are bacteria-derived
macrolides whose microtubule-stabilizing properties were
discovered in 1996 by a group at Merck Research Laborato-
ries [7]; the compounds themselves, however, had been first
isolated 9 years earlier from the myxobacterium Sorangium
cellulosum Sc 90 by Reichenbach and Höfle (Fig. 2) [8,9].
The major products originally isolated by Reichenbach
and Höfle were epothilone A and epothilone B (Epo A and B),
but numerous other members of this natural products family
have subsequently been obtained as minor components from
fermentations of myxobacteria [10]. Based on their unusual
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Fig. 3 Molecular structure of the anticancer drug ixabepilone
mechanism of action (at the time of its discovery), Epo A and
B were quickly adopted as attractive targets for total synthe-
sis and, more importantly, as lead structures for anticancer
drug discovery.
Epothilone-based drug discovery research was addition-
ally triggered by the fact that epothilones, in contrast to
taxol, can inhibit the growth of multidrug-resistant cancer cell
lines at concentrations similar to or only slightly higher than
those required against drug-sensitive cancer cells, [7,11–13]
including cells whose taxol resistance is mediated by spe-
cific tubulin mutations [13,14]. Epo B and a number of its
analogs have been demonstrated to possess potent in vivo
antitumor activity and at least seven epothilone-type com-
pounds have entered clinical evaluation in humans (although
several of these are not anymore under development). One
of these compounds, the epothilone B lactam BMS-247550,
was approved for clinical use in humans in 2007 (ixabepi-
lone, Ixempra), (Fig. 3) [15].
As indicated above, epothilones have been attractive tar-
gets for total chemical synthesis and numerous syntheses of
Epo A and B have been successfully completed (for reviews
cf. [16–22]). At the same time, the methodology developed
in the course of those studies has been exploited for the
synthesis of a host of synthetic analogs for SAR studies
(reviewed in [16,17,20,23–27]), which highlights the differ-
ence in structural complexity (and, consequently, in synthetic
accessibility) between epothilone-type structures and taxol.
Beyond the investigation of fully synthetic analogs, however,
important aspects of the epothilone SAR (structure–activity
relationship) have also been derived from numerous semi-
synthetic epothilone analogs and ixabepilone (Fig. 3), the
only epothilone that has reached the approval stage so far, in
fact is a semisynthetic derivative of Epo B.
Semisynthetic derivatives of natural products hold a
prominent place in natural product-based drug discovery in
virtually all disease areas [28,29]; due to the structural
complexity of many biologically active natural products
[30], the chemical derivatization of material isolated from
natural sources often represents the only practical means
to explore structure–activity relationships and to produce
analogs with improved biological and/or pharmaceutical
properties. In cancer treatment, important natural product
derivatives include compounds such as etoposide or tenipo-
side (derived from podophyllotoxin) [31–33], irinotecan and
topotecan (derived from camptothecin) [34–36], or doce-
taxel (derived from 10-deacetylbaccatin III) [5,37]. Even
for the natural product taxol [38], the sustained supply of
sufficient quantities of drug material for clinical use could
only be secured for some time through the development of a
semisynthetic production process from another natural prod-
uct, namely 10-deacetylbaccatin III [39,40]. Thus, it is not
surprising that semisynthetic approaches have also featured
prominently in the elucidation of the SAR of epothilones and
in the discovery of a number of clinical development candi-
dates. In fact, out of the seven epothilones that have entered
clinical evaluation in humans so far (including the natural
product Epo B), only one is produced by total chemical syn-
thesis. This bias towards semisynthesis reflects the technical
(fewer chemical steps) and economic (cost of goods) advan-
tages still associated with natural product derivatization.
Obviously, the most fundamental provision for the genera-
tion of semisynthetic derivatives of a natural product is a suf-
ficient supply of the natural product starting material itself.
Fermentation processes are characterized by their own com-
plexities; thus, in the case of epothilones, only few groups
have had access to fermentatively produced starting materi-
als to perform semisynthetic work. Thus, most semisynthetic
epothilone derivatives reported in the literature originate
either from the Höfle group at the former “Gesellschaft für
Biotechnologische Forschung” in Braunschweig, Germany
(GBF, now “Helmholtz Centre for Infection Research”), one
of the discoverers of epothilones, or the group at Bristol–
Myers–Squibb (BMS), either by themselves or in collabo-
ration [8,41]. Semisynthetic work on epothilones, although
more limited in scope, has also been reported by groups at
Novartis, Kosan, and, most recently, our own group at the
ETH Zürich.
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This review will provide an overview on the semisynthetic
work that has been reported for epothilones in the public lit-
erature over the last 15 years. The discussion will address
both, the organic chemistry of the system, as well as the
most important aspects of the biological activity and SAR of
these derivatives, and it will be structured according to the
location of groups of modifications in the overall epothilone
structural framework. This will facilitate the comparison of
the biological effects of related structural changes. However,
it is important to note that biological data (i.e., tubulin poly-
merization, in vitro and in vivo antiproliferative activity) may
not always be directly comparable when originating from
different laboratories, due to differences in the experimental
conditions employed.
Semisynthesis and SAR studies
Modifications of the epoxide moiety
Modifications of the epoxide moiety have been an important
trait of the semisynthetic work on epothilones from the very
beginning, which is unsurprising in light of the multitude
of transformations that are conceivable for an oxirane ring
and the potential for further elaboration of the initial reaction
products. The earliest contributions to this area stem from the
GBF group and involved the transformation of epothilones
A, B, and C (vide infra) into a variety of C12/C13-modified
derivatives [23]. Thus, treatment of Epo A with HCl in THF
(aq) or with 1M HCl gave chlorohydrins 1 and 2 in 60–80%
overall yield in a ca. 2–4:1 ratio (in favor of the C12-chloro
isomer 1; Scheme 1) [42].
The corresponding bromo- and iodohydrins were obtained
with bromine or iodine in CCl4/CHCl3, respectively, with a
ca. 3:1 preference for the C12-halo regioisomer in both cases
[42]. Preferential (but not completely selective) opening of
the epoxide moiety at position 12 upon treatment of Epo A
with different nucleophiles (HCl, MgBr2 ·Et2O, NaI/TMS-I,
LiN3, Mg(OMe)2) has also been reported by the Novartis
group [43]; in contrast, the reaction of Epo A with MgBr2 ·
Et2O in CH2Cl2 at −20◦C to −5◦C leads to the C13-bromo
isomer preferentially with less than 2% of the C12-regio-
isomer being formed [44,45] (vide infra). Due to the greater
stability of the C12 over the C13 carbocation in SN 1-type
reactions, treatment of Epo B with HCl gave chlorohydrin 7
as the only regioisomer in >80% yield (Scheme 2) [42].
Treatment of Epo A with a non-nucleophilic Brønsted acid
such as TFA led to rearranged products 3 and 4 exclusively
(85% combined yield), when acetone was used as the solvent
(Scheme 1) [42]. In contrast, exposure of Epo A or B to non-
nucleophilic acids in the presence of water gave diols 5/6
(Scheme 1) and 8 (Scheme 2), respectively. As for halohy-
drin formation, nucleophilic attack of the epoxide moiety in
Epo A occurs at position 12 preferentially, leading to isomer
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Scheme 1 a THF/HCl (aq) or 1 M HCl, RT, 20 min, 60–80%, 1:2, 2:1–4:1. b 0.65 M CF3COOH, acetone, 50◦C, 10 h, 50% (3) and 35% (4).
c 0.65 M CF3COOH, H2O, 23◦C, 48 h, 55% (5) and 15% (6). d p-TsOH, acetone, 28% (5a) and 15% (6a). (Yields for 5a and 6a are from [43])
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5 as the major (but not the only) product; with Epo B diol
8 is the only isomer formed. The rearranged products 3 and
4 show substantially lower antiproliferative activity against
human cancer cells than Epo A [42].
The GBF group has also used OsO4-catalyzed dihydroxy-
lation of fermentatively produced Epo C (12,13-deoxyepo-
thilone A) to prepare cis-diols 9 and 10 (Scheme 3); these
compounds were subsequently converted into acetonides 9a
and 10a (as were diols 5 and 6; Scheme 1) [42] (see also
[43]). Acetonides 5a/6a and 9a/10a have been independently
reported by the Novartis group [43], which has also investi-
gated the biological activity of these analogs.
Interestingly, the acetonides derived from 13S diols 5
and 9 (i.e., 5a and 9a) proved to be only 10–15-fold less
potent antiproliferative agents than Epo A against the human
cervical carcinoma cell line KB-31 and its P-gp-expressing
KB-8511 subline (IC50 values of 23 nM (10 nM) and 30 nM
(17 nM), respectively), while the respective diastereoisomers
6a and 10a were found to be 30–100-fold less potent [43];
likewise, Sefkow et al. [42] have reported 5a to have similar
antiproliferative activity as Epo C against the L929 mouse
fibroblast cell line. These data suggest that for a tetrahedral
geometry at C12 and C13 the size of the ring fused to the
C12–C13 single bond can be significantly increased with-
out substantial loss in biological potency (which does not
seem to be the case for analogs with a planar geometry of
the C12–C13 bond [43,46]). In addition, the data for 9a and
5a also illustrate that, given the proper absolute stereochem-
istry at C12 and C13, activity is retained even upon moving
from a cis- to a trans-fused system; this is in line with data
obtained for a number of synthetic C12,C13-trans epothil-
ones A [27]. It should be noted, however, that the absolute
configuration of compounds 5a and 9a (or the respective
diastereoisomers) has not been rigorously established in the
literature, and it is simply inferred from a comparison of the
biological data with those obtained for Epo A/epi-Epo A (the
inactive 12S,13R-isomer of Epo A) and 12S,13S/12R,13R-
trans-Epo A, respectively.
In contrast to the above acetonides, cis and trans diols 9
and 5 did not show any appreciable biological activity (IC50’s
for cancer cell growth inhibition >1 µM) [42,43]. Interest-
ingly, however, the azido alcohol obtained through epoxide
ring opening with NaN3 at position C12 (i.e., (12R, 13S)-
12-azido-13-hydroxy-12,13-dihydro-Epo C (11), Scheme 4)
was found to be significantly more potent (e.g., IC50’s of
11 against the human cervix cancer cell lines KB-31 and
KB-8511 are 61 and 64 nM, respectively) [43]. This indi-
cates that the loss in activity for the above diols cannot be
simply ascribed to increased conformational flexibility. How-
ever, the interpretation of changes in cellular activity is not
straightforward, as they may be caused by a combination of
changes in target affinity, cellular penetration, and metabolic
stability.
Building on the above findings on the potent activity
of acetonides 5a and 9a, we have recently studied bicy-
clic epothilones 13–15 (Scheme 4) and a series of related
analogs [48], in order to delineate the biological effects
of other 5-membered heterocycles fused to C12–C13 in
a non-planar arrangement and, in particular, to assess the
impact of substituents on the 5-membered ring. The synthe-
sis of Epo A-derived oxazolines 13–15 was based on amino
alcohol 12 as the central intermediate (Scheme 4). As illus-
trated in Scheme 4, 12 was obtained through nucleophilic
ring-opening of the epoxide moiety in Epo A with azide anion
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(to produce 11) and subsequent reduction of the azide group
under Staudinger conditions (Ph3P/H2O) [48]. The structure
of azido alcohol 11 (with a 12-azido group) as the major
product of the reaction between Epo A and LiN3 in DMF
in the presence of NH4Cl (the conditions employed in [48])
was firmly established by means of NMR spectroscopy. The
regiochemical course of the epoxide opening reaction is thus
identical with that reported for the reaction of 12,13-bis-epi-
Epo A with NaN3 in EtOH [45].
The elaboration of amino alcohol 12 into oxazolines
13-15 involved reaction of 12 with (commercially available)
triethyl-ortho-benzoate (13) or crude imino esters (14/15)
(Scheme 4); the latter were prepared from the corresponding
nitriles by treatment with HCl EtOH.
The phenyl-substituted oxazoline 13 was found to inhibit
human cancer cell growth in vitro with IC50 values around
20 nM [48]; thus, the activity of this analog is within a 10-
fold range of the activity of Epo A and it is comparable with
the activity of cyclic acetals 5a and 9a (vide supra). Quite
intriguingly, the cellular activity of pyridyl derivative 14 is
even >10-fold higher than for 13 and the IC50 values of this
compound for cancer cell growth inhibition are now com-
parable with those of Epo A. Likewise, 14 is also a potent
inducer of tubulin assembly, but the difference in polymeri-
zation efficiency between 14 and 13 is less pronounced than
the difference in antiproliferative activity [48]. It is, there-
fore, unclear to what extent (if at all) the enhanced cellular
activity of 14 (over 13) is a result of higher affinity interac-
tions with the tubulin/microtubule system (possibly through
H-bond formation between the pyridine nitrogen and a donor
group on the protein).
In contrast to the unsubstituted phenyl and pyridyl moi-
eties in 13 and 14, respectively, the presence of a p-tert-
butyl-phenyl substituent in the 2-position of the oxazoline
ring leads to a dramatic loss in potency; the corresponding
analog 15 no longer exhibits any meaningful antiproliferative
activity (IC50 > 10 µM) [48]. The lack of activity for 15 rep-
resents the culmination of a general SAR trend that points to
an inverse relationship between the size of a para-substituent
on an aryl moiety at the 2-position of the oxazoline ring and
antiproliferative activity.
Epo A or B can be deoxygenated and thus chemically
converted into Epo C and D (deoxyepothilones A and B),
respectively. In the case of Epo A, this transformation can
be achieved either with 3-methyl-2-selenoxo-benzothiazole
in CH2Cl2/CF3COOH (40%) [43] or with TiCp2Cl2/Mg in
THF (80%, Scheme 5) [49].
The Epo B → Epo D conversion seems to be best accom-
plished with WCl6 and n-BuLi in THF, which gave Epo D in
78% yield (Scheme 5) [49].
Biological studies with deoxyepothilones were first con-
ducted with fully synthetic material (Epo C and D are
advanced precursors in the total synthesis of Epo A and B,
respectively). These studies showed, at a very early stage,
that the oxirane ring is not an absolute structural requirement
for highly potent biological activity of epothilone-type mol-
ecules [50–53]. Thus, Epo C and D are virtually equipotent
inducers of tubulin polymerization as Epo A and B, respec-
tively; they are also potent inhibitors of human cancer cell
growth in vitro, including multidrug-resistant cells, although
compared to the corresponding parent epoxides their overall
activity is somewhat reduced. For example, Epo D inhibits
the growth of the human cervix cancer cell line KB-31 and the
leukemia cell line CCRF-CEM with IC50 values of 2.7 nM
[43] and 9.5 nM [54], respectively, versus IC50’s of 0.19 and
0.35 nM for Epo B. The reduced antiproliferative activity of
Epo D compared to Epo B may be related to differences in
cellular uptake between the two compounds [55].
The C12–C13 double bond in Epo C can be selectively
reduced (over the C16–C17 double bond) with in situ gen-
erated diimide to provide an analog with a completely sat-
urated macrocyclic core structure in 60% yield (98% based
on recovered starting material) [42]. This compound proved
to be several hundred-fold less active than Epo A [42].
The above methodology for the reduction of Epo A and B
to cis olefins Epo C and D, respectively, which was largely
developed by the BMS group, provided the basis for the
semisynthesis of cyclopropane-based analogs of epothilones,
which is exemplified in Scheme 5 for 12,13-cyclopropyl-Epo
A 17 [49]. The synthesis of 17 from Epo C proved to be highly
challenging, as the direct cyclopropanation of the 12,13-dou-
ble bond under Simmons–Smith conditions did not produce
any practical amounts of the desired product. In contrast,
treatment of TBS-protected Epo C with CHBr3/50% NaOH
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in the presence of benzyltriethylammmonium chloride at
45◦C gave dibromocyclopropane 16 as a single diastereo-
isomer, albeit in a very low yield of only 12%; nevertheless,
this process gave access to sizable quantities of the target
structure 17 (after reduction and deprotection, Scheme 5).
Cyclopropyl-Epo A 17 and the corresponding Epo B analog
were found to be equipotent with Epo A and B; e.g., IC50’s
for 17 and cyclopropyl-Epo B against the human colon carci-
noma cell line HCT-116 are 1.4 and 0.7 nM, respectively [49].
These findings re-confirmed the notion that the oxirane ring
system in epothilones merely serves to stabilize the proper
bioactive conformation of the macrocyclic skeleton rather
than acting as a reactive electrophile or a hydrogen bond
acceptor. As shown in a later study by Buey et al. [56], the
replacement of the epoxide moiety by a cyclopropane ring
also produces enhanced binding to stabilized microtubules
in vitro. Bis-substitution of the oxygen-replacing carbon in
cyclopropyl-Epo B by bulky bromine substituents leads to
reduced activity, but the resulting analog is still more potent
than Epo D against the HCT-116 cell line (IC50 against HCT-
116 of 3.8 nM versus 6.5 nM for Epo D [49]).
In addition to cyclopropyl-epothilones, the BMS group
has also devised a strategy for the conversion of Epo A to
a whole range of analogs incorporating a (substituted) aziri-
dine ring in place of the epoxide moiety [45].
As illustrated in Scheme 6, the optimized route to these
compounds involves regioselective epoxide ring-opening
with MgBr2 · Et2O (at C13!) followed by bromide displace-
ment with azide ion, Mitsunobu-based inversion of config-
uration at C12, activation of the 12-hydroxyl group as a
mesylate and finally aziridine ring formation through azide
reduction under Staudinger conditions. The resulting N-un-
substituted 12,13-aziridinyl-Epo A 21 has been converted
into a series of N-substituted derivatives via alkylation, acyla-
tion, carbamoylation, or sulfonylation. Several of these deriv-
atives show antiproliferative activities that are comparable
with or even superior to that of Epo A [45]. (For example,
IC50’s for 21 and 22 against the human colon carcinoma
cell line HCT-116 are 2.7 and 0.13 nM, respectively). Most
recently, a folate conjugate of the N-(hydroxyethyl)-deriva-
tive of 21 (epofolate, BMS-753493) has been advanced by
BMS to two Phase I/II clinical studies; these studies were
terminated as of July 2010 [57].
Bromohydrin 18 (Scheme 6) has also been elaborated
into 12-cyano-Epo A 24 which was expected to be more
acid-stable than the natural product Epo B (Scheme 7) [44].
As outlined in Scheme 7, oxidation of 18 with pyridinium
chlorochromate (PCC) furnished bromo ketone 23, whose
treatment with KCN led to cyanohydrin formation and con-
comitant epoxide ring closure. Deprotection with CF3COOH
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then provided the target structure 24. Interestingly, chloro-
hydrins 1, 2, and 7 (Schemes 1 and 2) have been reported not
to undergo epoxide formation even under strongly basic con-
ditions [42], in contrast to the facile formation of the epoxide
ring from the cyanohydrin of ketone 23. The antiprolifera-
tive activity of 12-cyano-Epo A (24) is comparable with that
of Epo A (i.e., the compound is highly potent, but the activ-
ity is lower than that of its (C12-methyl) parent compound
Epo B).
Modifications of the ester moiety
One of the most obvious modifications of the epothilone scaf-
fold is the hydrolysis of the ester bond to produce the corre-
sponding seco acid.
This transformation has been achieved by treatment of
Epo A with NaOH/MeOH, which gave seco acid 25 in 65%
yield (Scheme 8); however, ester hydrolysis was also accom-
panied by the retro aldol cleavage of the C3–C4 bond, thus
leading to 23% of the retro aldol product 26 (Scheme 8) [58].
Ester hydrolysis is also possible with pig liver esterase (PLE)
as a catalyst and this provides for a more selective course of
the reaction [8].
Seco acid 25 can be further degraded to ester 27 and diol
28 via acid-catalyzed epoxide hydrolysis followed by ester-
ification with TMS-diazomethane, periodate cleavage of the
12,13-diol, and finally borohydride reduction of the mixture
of cleavage products. Compounds 27 and 28 may be used
as chiral building blocks for the synthesis of other complex
target structures. No primary data on the biological activity
of 25 have appeared in the literature, but the compound has
been reported by the Novartis group to be several 1000-fold
less active in cell proliferation assays than Epo B in a number
of presentations. These reports are in line with observations
by the BMS group on the significantly diminished in vitro
cytotoxicity of epothilones when preincubated with mouse
plasma, which leads to rapid ester cleavage [59]. While the
situation is more complex in vivo and the stability of Epo B
is much higher in human than in rodent plasma, their find-
ings on the reduced activity of epothilones in the presence
of mouse plasma have led the BMS group to pursue lactam-
based epothilone analogs as metabolically more stable alter-
natives to the natural macrolactones [41,59]. In the course of
this work, the group has developed a very elegant approach
for the preparation of the macrolactam analogs of Epo A and
B. The process exploits the allylic nature of the ester group in
epothilones and involves Pd(0)-catalyzed ring opening and
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Scheme 8 a NaOH/MeOH, RT, 5 min, 65% (25) and 24% (26). b 1. H2SO4, THF/H2O, RT, 5 h. 2. TMSCHN2, 2.5 h, 54%. c 1. NaIO4, MeOH/H2O,
RT, 45 min; 2. BH−4 -ion exchange resin, 41% (27) and 49% (28)
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Scheme 9 a Pd(PPh3)4, NaN3, THF/H2O, 45◦C, 1 h, 29: 60%, 30: 70%. b PtO2, H2, 20 h, 31: 89%, 32: 53% or Me3P, THF, 45◦C, 14 h, 70%
(32). c DPPA, NaHCO3, DMF, 4◦C, 24 h, 43% (34) or EDCI, HOBt, MeCN/DMF, ca. 65% (34)
trapping of the ensuing Pd-π complex with a nitrogen nucle-
ophile. Thus, the treatment of Epo A or B with NaN3 in the
presence of Pd(PPh3)4 led to azido acids 29 and 30, respec-
tively, with full retention of configuration at C15 (Scheme 9).
Reduction of the azide group either through catalytic
hydrogenation or with trimethyl phosphine led to amino
acids 31 and 32, respectively, which could be ring-closed
to furnish the lactam analogs of Epo A and B, 33 and 34,
respectively. Using this chemistry, the BMS group has also
developed an efficient one-pot process for the conversion of
Epo B into lactam derivative 34, which involves the above
Pd(0)-catalyzed ring-opening reaction, reduction of the azide
with trimethyl phosphine and macrolactam formation with
EDCI/HOBt [59]; this provides the desired lactam in 23%
overall yield.
Epo B lactam 34 (BMS-247550, ixabepilone) is a potent
inducer of tubulin polymerization, but its antiproliferative
activity is ca. one order of magnitude lower than that of Epo
B [23,59] (e.g., IC50 values against the human colon carci-
noma cell line HCT-116 are 3.6 and 0.42 nM, respectively, for
34 and Epo B [59]). Similar differences have been reported
between the lactam analogs of Epo A (33), Epo C and
Epo D and the respective parent macrolactones; methyla-
tion of the lactam nitrogen in 33 results in a substantial loss
in potency [60].
In contrast to natural epothilones, 34 is significantly
less active against the highly P-gp overexpressing, multi-
drug-resistant KB-8511 variant of the KB-31 cell line than
the drug-sensitive KB-31 parental line (IC50’s of 2.85 and
128 nM against KB-31 and KB-8511 cells, respectively [23]).
This indicates that 34 is at least a moderate P-gp substrate, a
conclusion which is also supported by data obtained for other
lactam-based epothilone analogs [61]. In vivo 34 exhibits
antitumor activity similar to that of Taxol in Taxol-sen-
sitive tumor models (i.e., A2780 human ovarian carcinoma,
HCT-116 and LS174T human colon carcinomas) [62]. In
spite of its limited effects against highly multidrug-resistant
cell lines in vitro, intriguingly, the compound has also been
found to be superior to Taxol in Taxol-resistant tumor
models [62].
Based on its highly compelling preclinical profile Epo B
lactam 34 was selected by BMS for clinical development (as
BMS-247550 or ixabepilone) and in 2007 was approved by
the FDA for the treatment of metastatic or advanced breast
cancer, either as single agent or in combination with capecit-
abine [15]; the drug is marketed in the US by Bristol-Myers
Squibb (BMS) under the trade name Ixempra.
Modifications in the C2–C8 region
Semisynthesis-based modifications in the C2–C8 region have
involved transformations of all functional groups present in
this sector of the epothilone structure, including the hydroxyl
groups at C3 and C7 as well as the keto group at C5. Epo A and
B can be readily converted to the corresponding C3/C7-bis-
formyloxy derivatives 35 and 36 (Scheme 10), which can then
be further transformed into the α, β-unsaturated lactones 37
and 38, respectively, by treatment with NH3/MeOH, which
results in selective based-induced elimination of formic acid
across the C2–C3 bond and concurrent cleavage of the for-
mate ester at C7 [44].
After TES protection of 37 and 38, to give 39 and 40,
1,4-addition of cyanide ion produced a ca. 1/1 mixture of 3S
and 3R isomers, which were separated and then deprotected
with acetic acid individually to provide 41 and 42 (as well
as their corresponding 3R isomers). The in vitro activity of
analogs 37/41 and 38/42 is less than one order of magnitude
lower than that of Epo A and B, respectively; for 38 and 42
their in vitro antiproliferative activity is thus comparable with
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Scheme 11 a PDC, CH2Cl2, RT, 36 h, 80%. b (CH3)2S, (PhCO2)2, MeCN, 0◦C → RT, 24 h, 30%
taxol [44]. In contrast, the 3R isomers of 41 and 42 exhibit
significantly reduced activity [44].
The GBF group has also investigated oxidative and reduc-
tive transformations in the C2–C8 region of Epo A, using a
variety of different conditions [47]. Thus, treatment of Epo
A with neutral pyridinium dichromate (PDC) in CH2Cl2 or
DMF provided acetal 43 in 80% yield (Scheme 11), while
oxidation under Swern conditions or with acidic PDC was
either less selective or produced complex reaction mixtures,
respectively [47]. Selective oxidation of the hydroxyl group
on C3 in Epo A is more difficult and could only be accom-
plished in very moderate yield with a mixture of dimeth-
ylsulfide and dibenzoylperoxide [47]. No oxidation of the
7-OH group takes place under these conditions, but the oxi-
dized product is obtained as its C7-methylthiomethyl (MTM)
ether 44 (30% yield; Scheme 11). The compound is present
as a 2/3 mixture of keto/enol isomers [47]. In addition to
44, the reaction also produced the C7-mono-MTM and the
C3,C7-bis-MTM ethers of Epo A, each in about 30% yield.
The C5-keto group in Epo A can be selectively reduced
with NaBH4 in a THF/pH 7 buffer system, to give a 1:1
mixture of diastereomeric C5-alcohols (ca. 70%). Interest-
ingly, unbuffered reaction conditions led to rapid cleavage
of the ester bond [47]. Treatment of 43 with NaBH4 in
MeOH resulted in the selective reduction of the C5-keto
group without any effect on the C7-ketone, although 43 has
been reported to exist in a 97/3 equilibrium mixture between
the cyclic acetal and the keto alcohol form (which, in princi-
ple, should also make it susceptible to reduction at C7).
Acetal 43 retains some activity against the mouse leuke-
mia cell line L929 (IC50 of ca. 400 nM [47] versus 8 nM for
Epo A [63]), while oxidation at C3 or reduction at C5 lead
to IC50 values of > 1 µM [47].
Side chain modifications
The C15 side chain of epothilones has been targeted for semi-
synthesis in a number of different ways that include modifi-
cations (or replacement) of the heterocycle, the vinyl linker
between the heterocycle and the macrolactone ring, or both.
Quite intriguingly, given the type functionality present in the
macrolactone core, the treatment of Epo A with an excess
of n-BuLi in THF at −90◦C and subsequent quenching with
different electrophiles has allowed the preparation of a num-
ber of C19-substituted Epo A derivatives in modest yields
(Scheme 12) [64]. As an unfortunate exception, C19-fluoro
Epo A could not be obtained with a range of fluorinating
agents.
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Scheme 12 a n-BuLi (5 equ), THF, −90◦C, electrophile (CCl4, NBS,
I2, DEAD, HCONMe2, Me3SiCl). 45: 50%; 46: 15%; 47: 25%; 48:
50%; 49: 30%; 50: 35%
In some cases, deprotonation also occurred at C21 (in
addition to C19), albeit to a lower extent. Only with EtI as
the electrophile reaction took place exclusively at C21, lead-
ing to C20-desmethyl-C20-propyl-Epo A as the only isolable
product in 8% yield (40% based on recovered starting mate-
rial). All of the C19-modified Epo A analogs were found to
be significantly less active than the parent natural product in
cancer cell proliferation assays [64].
While not accessible by base treatment and subsequent
electrophilic quenching, C21-substituted epothilone deriva-
tives can nevertheless be obtained through semisynthesis in
a very efficient manner. As illustrated in Scheme 13 for Epo
B as the starting material, Epo A and B can be converted
to the corresponding C21-hydroxyl derivatives Epo E and F,
respectively, through a Polonovski-type [65] rearrangement
[63].
Thus, treatment of Epo B with m-chloroperbenzoic acid
(m-CPBA) produced the thiazole N-oxide 51, which rear-
ranged to C21-trifluoroacetoxy-Epo B upon reaction with
trifluoroacetic anhydride. Treatment of this intermediate with
NH3 (aq) in THF then gave Epo F (52) in 38% overall yield
(for the 3-step sequence from Epo B). In a completely anal-
ogous way, Epo A could be converted into Epo E [63].
Epo E and F, which have also been isolated from fer-
mentations of myxobacteria, exhibit similar antiproliferative
activity as Epo A and B, respectively, against drug-sensi-
tive cell lines, but are somewhat less potent against P-gp-
overexpressing multidrug-resistant lines. (For example, IC50
values of 0.23 and 0.94 nM have been reported for Epo F
against the drug-sensitive and drug-resistant human cervix
carcinoma cell lines KB-31 and KB-8511, respectively [23]).
Quite intriguingly, the activity of N-oxide 51 is also compa-
rable with that of Epo B [63].
Both Epo E and F have been elaborated into different
C21-modified derivatives [66] and C20 substituents of lim-
ited size (but still larger than the natural methyl group) have
been found compatible with potent antiproliferative activity;
more bulky substituents result in a substantial loss in potency.
Most of the corresponding analogs have been obtained by
total synthesis rather than semisynthetic transformations or
were isolated from fermentations of myxobacteria (including
Epo E and F, vide supra) [10]. However, semisynthesis from
Epo B (via Epo F (52)) has served to prepare C21-amino-Epo
B (54), which has been advanced to Phase I clinical studies
by BMS (as BMS-310705 [25]). As outlined in Scheme 14,
BMS-310705 (54) could be prepared from Epo F via azide
53, which was obtained by treatment of 52 with diphenyl-
phosphoryl azide (DPPA); Staudinger reduction of 53 with
PMe3 then gave the desired 54 [25].
Only limited biological data have been disclosed for 54
so far. Based on a patent application [67], the compound
shows an IC50 value of 0.8 nM against the human cervix
cancer cell line KB.31 (versus 1.2 nM for Epo B under com-
parable experimental conditions [63]); it was also demon-
strated to induce substantial apoptosis in early passage, taxol-
and platinum-refractive ovarian cancer cells (OC-2) at a
concentration of 50 nM [68]. BMS-310705 (54) exhibits
improved water-solubility over BMS-247550 (34), which
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enables the use of clinical formulations not containing
Cremophor-EL [25].
Phase I clinical development has also been reported
for C20-desmethyl-C20-methylsulfanyl-Epo B (55, ABJ879;
Novartis) (Fig. 4).
Like BMS-310705 (54), 55 is a semisynthetic Epo B deriv-
ative [69], but the route for its preparation has not been dis-
closed in the literature. ABJ879 (55) is a markedly more
potent antiproliferative agent than Epo B, with an average
IC50 for growth inhibition across a panel of drug-sensitive
human cancer cell lines of 0.09 nM (vs. 0.24 nM for Epo B
and 4.7 nM for taxol) [69]. The compound retains full activ-
ity against cancer cells overexpressing the drug efflux pump
P-gp or harboring tubulin mutations.
ABJ879 (55) has demonstrated potent antitumor activ-
ity in experimental animal models [69], where it produced
transient regressions and inhibition of tumor growth of slow-
growing (NCI H-596 lung adenocarcinomas, HT-29 colon
tumors) as well as fast-growing, difficult-to-treat tumors
(NCI H-460 large cell lung tumors). In addition, single dose
administration of ABJ879 (55) produced long-lasting regres-
sions and cures in a Taxol-resistant KB-8511 cervix carci-
noma model [69]. In spite of these favorable preclinical data,
the clinical development of ABJ879 (55) was discontinued
after Phase I for undisclosed reasons [70]; the same appears
to be true for BMS-310705 (54).
As indicated above, semisynthetic modifications of the
epothilone side chain are not confined to variations in het-
erocycle substituents, but also include manipulation of the
C16-C17 double bond. The latter can be epoxidized with
m-CPBA or dimethyl dioxirane (DMDO) in low to moder-
ate yield to furnish 56 as a 3/2 mixture of diastereoisomers
(Scheme 15). Subsequent hydrogenolysis over Pd/C in EtOH
gave a mixture of epimeric C16-alcohols in quantitative yield
(i.e., hydrogenation occurred selectively at the position α to
the thiazole ring, Scheme 15) [47].
The C16–C17 double bond can be completely cleaved
by means of ozonolysis (O3, CH2Cl2, −70◦C, 10 min, then
(Me2S) [47]; the resulting ketone 58 (in the case of Epo
A) was immediately reacted with trimethylsilyl (TMS) chlo-
ride to provide bis-TMS ether 59 in 70% overall yield
(Scheme 16). Ketone 58 could be readily transformed into
O-substituted oximes 61 and 62 [47] and it was also elabo-
rated into imidazole-containing analog 63 through base-cat-
alyzed aldol condensation [71,75] (Scheme 16). In contrast,
olefination reactions involving the C16 keto group proved to
be highly problematic. While 59 could be converted to meth-
ylene derivative 60 in a modest overall yield of 15% (after
deprotection), all attempts to re-introduce the natural thiazole
side chain or to create a phenyl-based Epo A analog using
Wittig-type chemistry were unsuccessful [47,71,75]. How-
ever, the successful and unproblematic instalment of the thi-
azole side chain through Wittig olefination has been reported
for a methyl ketone formally derived from E-9,10-dide-
hydroEpo D; the latter was prepared by total synthesis [77].
The reasons for this discrepancy have not been investi-
gated. All analogs depicted in Scheme 16 were found to be
significantly less active in proliferation or tubulin assays than
Epo A [47,71,75].
In order to enable the replacement of the thiazole ring
by other (hetero)aryl moieties, Höfle and co-workers have
developed an alternative strategy for the construction of the
aryl-vinyl part of the epothilone side chain from ketone 59
(Scheme 17).
The approach is based on the conversion of 59 to boronic
acid 64, which was accomplished in 83% yield with the
bisboryl methyl lithium reagent 65. While 64 was obtained
as a 7/3 mixture of E/Z double bond isomers, these could be
separated by preparative HPLC and the pure E-isomer was
converted to the protected phenyl-based Epo A analog 66
through Suzuki coupling [71,75]. Alternatively, reaction of
E-64 with N-iodosuccinimide (NIS) gave the correspond-
ing vinyl iodide, which underwent smooth Stille coupling
with stannane 67 to give 68 [71,75]. No activity data have
been reported for the (deprotected version of) thiophene
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Scheme 15 a m-CPBA, CH2Cl2, RT, 1 h, 10% or DMDO, acetone, 0◦C → RT, 5 h, 25% (3/2 mixture of isomers). b) H2, 10% Pd-C, EtOH, RT,
90 h, quant
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Scheme 17 a 1. 65, CH2Cl2/THF; 2. hydrolysis, 83% (E/Z , 7/3). b N-iodo succinimide. c 67, Pd(PPh3)4. d PhI, Pd(PPh3)4, TlOEt, EtOH.
No yields are reported in [70] for steps b, c, and d; likewise, the deprotection of 66 and 68 has not been described
derivative 68; the phenyl analogs of Epo C and Epo B have
been reported by others to retain most of the activity of the
thiazole-containing parent compounds [77].
Replacement of the C13-O16 segment
Semisynthetic epothilone analogs have also been prepared
via intermediates that were obtained through the degrada-
tive removal of the entire C13-O16 segment (including the
pendant side chain), which were then (re)elaborated into
modified versions of the original structure. The first imple-
mentation of this concept was reported by the GBF group,
who used ring-opening olefin metathesis (ROM) with ethyl-
ene for the conversion of Epo C into the ring-opened prod-
uct 69 in 73% yield (employing Grubbs II catalyst) [73]
(Scheme 18).
Diene 69 was then further elaborated into protected acid 71
through TBS-protection (at −20◦C) and selective cleavage of
the TBS-ester with an excess of TBSOTf (at 30◦C). Esteri-
fication of 71 with alcohol 72 provided yne-diene 74, which
underwent smooth ring-closingolefinmetathesis (RCM)with
Grubbs I catalyst to reconstitute the macrocyclic epothilone
framework in the form of 12/13-deoxy analog(s) 75 (obtained
as a 1/1 mixture of E/Z -isomers in 52% yield). After depro-
tection of 75 with CF3COOH the E- and Z -isomers could be
separated and were isolated in 43% yield each. Epoxidation
of the Z -isomer with DMDO gave Epo A analog 76 in 61%
yield (together with 33% of its 12S,13R isomer). 76 (as well
as its 12,13-deoxy derivative) showed significantly reduced
antiproliferative activity against the mouse fibroblast cell line
L929, relative to Epo A (IC50 values > 1 µM versus 8 nM for
Epo A [63]) [73].
More recently, an approach similar to the one depicted
in Scheme 18 has been developed by Dong et al. at Kosan,
who have converted fermentatively produced Epo D into keto
ester 77 (Scheme 19) [74]. In contrast to Höfle’s approach,
cleavage of the 12,13-double bond in this case involved
stoichiometric OsO4-mediated dihydroxylation followed by
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Scheme 18 a CH2=CH2, Grubbs II catalyst (0.15 equ), 44 h, 73%
(83% based on recovered starting material). b TBSOTf, 2,6-lutidine,
CH2Cl2, −20◦C, 24 h, 75%. c) TBSOTf, 2,6-lutidine, 30◦C, 2 h, 94%.
d DCC, DMAP, 72, 0◦C → RT, 16 h, 91%. e) Grubbs I catalyst
(0.2 equ), CH2Cl2, RT, 48 h, 52% (1/1 mixture of E/Z -isomers). f
CF3COOH/CH2Cl2 6/1, 0◦C, 2 h, 43% (+ 43% of 12,13E-isomer). g
DMDO, CH2Cl2/acetone, −20◦C, 2 h, 61% (+32.5% 12S,13R isomer)
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Scheme 19 a TBSOTf, Et3N, CH2Cl2, −78◦C, 85%. b OsO4,
TMEDA, −78◦C, then NaHSO3, 65◦C, 75%. c Pb(OAc)4, ben-
zene, then K2CO3, MeOH. d TMSCHN2, MeOH, toluene, 81% (2
steps). e Cp2TiMe2, toluene, 80◦C, 74%. f LiOH, i-PrOH/H2O,
86%. g 79, EDC, DMAP, CH2Cl2, 54–82%. h CH2Cl2, Grub-
bs II catalyst, refl., 8 h, 60% (1/1 mixture of E/Z -isomers).
i CF3COOH, CH2Cl2, 0◦C → RT or HF·pyridine, THF, 0◦C → RT,
32–59%
oxidative cleavage of the resulting 12,13-diol with Pb(OAc)4
(rather than ROM).
Treatment of the crude keto aldehyde thus obtained with
K2CO3 led to facile elimination of the C1-C12 segment
as the free carboxylic acid, which was converted to ester
77 with TMS-diazomethane. Petasis olefination followed
by ester saponification and re-esterification of the resulting
acid 78 with alcohol 79 then provided diene 80. The latter
underwent RCM in the presence of Grubbs II catalyst, fur-
nishing the desired macrolactone as a 1/1 mixture of E/Z
isomers about the C12/C13 bond in 60% total yield.
Isomer separation was possible after deprotection of the mix-
ture with CF3COOH. Analog 81 was found to be 2-3-fold
less potent than Epo D in cancer cell proliferation assays
[74]; in contrast, fully synthetic Epo B and D analogs incor-
porating benzothiazole-, quinoline-, or benzimidazole side
chains had been shown previously to be more potent than
the corresponding parent compounds [27]. In fact, one of
the epothilone-type clinical development compounds (ZK-
Epo, sagopilone) is an analog of Epo B with a benzothia-
zole side chain (analogous to the benzoxazole side chain in
analog 81) [75]; however, sagopilone could not be prepared
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Scheme 20 a PLE. b TMSCHN2, 25% (2 steps, plus recov-
ered starting material). c TBSOTf, 44%. d O3, Ph3P, 86%. e
NaClO2, NaH2PO4, 43%. f EDC, HOBt, Et3N, 79%. g LiOH, 86%.
h 2,4,6-trichlorobenzoyl chloride, 37%. i CF3COOH, 56%. j
NaBH(OAc)3, 74% (with amine 84). (Yields for steps f–i are for inter-
mediates leading to 86)
according to the approach shown in Scheme 19, as it also
includes a C6-allyl substituent in place of the natural methyl
group [75].
Employing PLE-catalyzed hydrolysis of the lactone group
and subsequent cleavage of the C12/C13 double bond by
ozonolysis, the BMS group was able to establish the con-
trolled degradation of Epo C into ester 82 (Scheme 20).
Oxidation of 82 with NaClO2 gave the mono-ester of a
dicarboxylic acid, which could be coupled with amines 83
or 84, to give the C12–C13 amide-based analogs 85 and
86, respectively, after ester saponification, Yamaguchi-type
macrolactonization and final deprotection with CF3COOH
(Scheme 20) [41]. Alternatively, 82 and amines 83/84 were
submitted to reductive amination and the resulting secondary
and tertiary amines were elaborated into 13-aza epothilones
87 and 88, respectively (Scheme 20). Unfortunately, none of
the derivatives 85–88 showed any significant tubulin-poly-
merizing or growth-inhibitory activity. In contrast, different
(fully synthetic) N12-acyl- or carbamoyl-substituted 12-aza-
epothilones have been shown to exhibit very potent biological
effects [76].
Conclusions
The work discussed in this review article has defined the
chemistry associated with the epothilone molecular frame-
work in significant detail. This chemistry has enabled the
preparation of a large number of structurally modified, semi-
synthetic epothilone derivatives, which have contributed
significantly to our current understanding of the epothilone
SAR by complementing the results obtained with fully syn-
thetic analogs. Most importantly, these efforts have led to
the discovery of three derivatives that have been advanced to
clinical studies in humans. Thus, notwithstanding the wealth
of fully synthetic analogs that have been prepared over the
last 15 years and many of which exhibit very attractive bio-
logical profiles (at least in vitro), semisynthesis so far has
had the more profound impact on the clinical advancement
of the epothilone class of microtubule stabilizers than total
synthesis.
At the same time, it is clear that the potential of semisyn-
thesis for the creation of new structurally unique epothilone
analogs is far from being exhausted. Many additional deriv-
atives with a diverse range of structural features are con-
ceivable that should be chemically accessible from natural
epothilones as starting materials and that might exhibit inter-
esting biological properties. However, the further exploration
of semisynthetic approaches towards new epothilones ana-
logs is limited by access to the fermentatively produced start-
ing materials. It is unclear at this point, whether those groups
with a sufficient supply of natural epothilones (BMS, GBF
(now Helmholtz Centre for Infection Research), Novartis)
continue to be active in the area of epothilone semisynthesis.
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